摘要
RESOLVE研究为一项3期开放、多中心、随机、对照临床研究,旨在为中国人群提供进展期胃癌围手术期治疗方案。研究纳入cT;期患者,比较了SOX(奥沙利铂+替吉奥)辅助化疗和CapOx(奥沙利铂+卡培他滨)辅助化疗以及SOX新辅助化疗与CapOx辅助化疗的疗效,证实SOX新辅助化疗对于中国人群进展期胃癌的优效性。RESOLVE研究为针对中国进展期胃癌患者围手术期治疗方案研究的良好开端,然而,该研究及国际上其他大型研究(MAGIC、FLOT4)均非相同化疗药物新辅助治疗与辅助治疗的直接比较,期待后续进行完善,并结合组织学分类、基因分型,进行更精准的治疗方案研究。
RESOLVE study is an open,multicenter,randomized,controlled clinical phase 3 study,aimed at providing perioperative treatment for advanced gastric cancer in Chinese population.This study included cT4 patients,compared the efficacy of SOX(oxaliplatin+teggio)adjuvant chemotherapy with CapOx(oxaliplatin+capecitabine)adjuvant chemotherapy,SOX neoadjuvant chemotherapy and CapOx adjuvant chemotherapy,and confirmed the superiority of SOX neoadjuvant chemotherapy for advanced gastric cancer.The RESOLVE study is a good start for the research on the perioperative treatment scheme in Chinese patients with advanced gastric cancer.However,this study and the international large-scale studies MAGIC and FLOT4 are not the direct comparison of neoadjuvant and adjuvant therapy based on the same chemotherapy drugs.The forward clinical researches of the more accurate perioperative treatment scheme for advanced gastric cancer based on the tissue classification and genotyping would be expected.
作者
蔡慧
聂明明
CAI Hui;NIE Ming-ming(Department of Gastrointestinal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,China)
出处
《中国临床医学》
2022年第1期1-6,共6页
Chinese Journal of Clinical Medicine
基金
上海市科委自然基金面上项目(19ZR1456100)。
